Corrigendum

Corrigendum to “The Controversial C5a Receptor C5aR2: Its Role in Health and Disease”

Ting Zhang, Malgorzata A. Garstka, and Ke Li

Core Research Laboratory, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China

Correspondence should be addressed to Ke Li; ke.li@mail.xjtu.edu.cn

Received 10 September 2017; Accepted 16 October 2017; Published 1 November 2017

Copyright © 2017 Ting Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “The Controversial C5a Receptor C5aR2: Its Role in Health and Disease” [1], there was an error in Table 4, where Jun/fos-A8^{Δ71–73} should be corrected to A8^{Δ71–73}. The corrected table is as follows:

TABLE 4: C5aR2 agonists and antagonists.

Ligand	Specificity	Function	Refs
Jun/fos-A8 A8 ^{Δ71–73} C5 mutant peptides	Human and murine C5aR1 and C5aR2	Antagonists—block binding of C5a and C5a des Arg to C5aRs	[51]
P32, P59—C terminal peptides of C5a	hC5aR2	Agonists—strongly stimulate the association of hC5aR2 with β -arrestin 2	[21, 127]
LukS-PV—protein from <i>S. aureus</i>	Human and rabbit C5aR1 Human, macaque, and rabbit C5aR2	Antagonist of C5a-induced activation of neutrophils	[48, 128]
HIgCB—protein complex from <i>S. aureus</i>	Human, macaque, rabbit, and cow C5aRs	Antagonist of C5a-induced activation of neutrophils	[128, 129]

References

- [1] T. Zhang, M. A. Garstka, and K. Li, “The controversial C5a receptor C5aR2: its role in health and disease,” *Journal of Immunology Research*, vol. 2017, Article ID 8193932, 16 pages, 2017.